Akari Therapeutics furthers clinal trials for Covid-19 pneumonia

• Akari Therapeutics (AKTX -1.6%) announces further progress in its COVID-19 pneumonia program with nomacopan in the U.S. and Brazil.
• Nomacopan’s dual complement and leukotriene inhibition has applicability in a range of other severe lung inflammatory conditions
• COVID-19 pneumonia is believed to be a major cause of death in patients with COVID-19 and despite improvements in standard of care, remains difficult to treat.
• Both studies in the U.S. and Brazil are double blind randomized clinical studies of over 60 patients each, with a primary endpoint of time to oxygen normalization and hospital discharge.
• Press Release
• https://seekingalpha.com/news/3620183-akari-therapeutics-furthers-clinal-trials-for-covidminus-19-pneumonia